ESNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ESNT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near short-term resistance, technicals are overbought, insider selling is elevated, and there is no recent news or earnings catalyst to improve conviction. Analyst sentiment is mixed but still generally constructive, so the stock is not a sell either; the better call today is to hold and wait for a cleaner entry.
ESNT is in a short-term uptrend but looks stretched. The MACD histogram is positive at 0.734, which supports bullish momentum, but it is contracting, suggesting the move is losing strength. RSI_6 is 81.4, which is clearly overbought and usually signals the stock may be due for consolidation. Moving averages are converging, showing the trend is not strongly accelerating. Price at 63.60 sits just below R1 at 64.49, with pivot support at 61.77 and deeper support at 59.05. Overall, the trend is constructive but not an ideal fresh entry for a long-term beginner right now.
["Keefe Bruyette raised its price target to $74 and keeps an Outperform rating.", "Keefe Bruyette upgraded the stock to Outperform on valuation grounds.", "BofA keeps a Buy rating and raised its target to $69.", "The stock has support from analyst valuation arguments, with some firms noting it screens cheap versus tangible book value.", "Similar candlestick pattern analysis suggests modest upside probabilities over the next day, week, and month."]
["No news in the recent week, so there is no fresh catalyst to drive a near-term rerating.", "Insiders are selling, and selling increased 184.94% over the last month.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Recent analyst commentary has been mixed, including a target cut from Roth Capital and cautious language about slow growth in the mortgage insurance business.", "The options market shows a high put-call open interest ratio of 2.53, leaning defensive.", "RSI is overbought, raising the risk of near-term consolidation instead of immediate upside continuation."]
No usable latest-quarter financial snapshot was provided, so I cannot assess revenue or earnings growth trends for the most recent quarter season. Based on the analyst commentary available, the business is described as mature with slow growth conditions, and mortgage insurance demand is being constrained by affordability and higher rates.
Analyst sentiment is mildly positive but not strongly aligned. Recent actions include Keefe Bruyette upgrading ESNT to Outperform and then raising the target to $74, BofA maintaining a Buy with a $69 target, and Barclays/JPMorgan keeping more neutral stances around the low-to-mid $60s. Roth Capital lowered its target to $65 but kept Buy. Overall, Wall Street sees value and some upside, but the view is mixed: pros highlight cheap valuation relative to book value, while cons center on slow growth, higher-rate pressure, and more limited upside than a strong momentum name.
